Membrane Protein Targeting in Mycobacterial Drug Development

The impermeable cell envelope of Mycobacterium species presents a formidable barrier to chemotherapy, underpinning the persistence of diseases such as tuberculosis. Central to this barrier are specialised inner‐membrane transporters of the resistance-nodulation-division superfamily, notably the MmpL (mycobacterial membrane protein large) proteins, which mediate the export of key lipid components—including mycolic acids and siderophores—that are essential for cell-wall integrity and nutrient acquisition. Advances in structural biology have begun to elucidate the three-dimensional architecture of these transporters, revealing conformational changes driven by proton motive forces and identifying binding pockets for substrate and inhibitor molecules. Small-molecule inhibitors that obstruct these conformational cycles or lock transporter domains in inactive states have demonstrated potent bactericidal activity. By integrating high-resolution structures, dynamic simulations and functional reconstitutions, current research is forging new avenues for the rational design of anti-mycobacterial agents that target membrane protein function and compromise the protective envelope of the pathogen.

Research from Nature Portfolio

A seminal study established the essentiality of the MmpL3 transporter by constructing a conditional knockdown strain of M. tuberculosis. Controlled depletion of MmpL3 induced rapid bacterial death, coinciding with intracellular accumulation of trehalose monomycolate precursors and profound transcriptional shifts affecting energy metabolism and envelope biogenesis. The work demonstrated that impairing MmpL3 function disrupts outer-membrane assembly, perturbs ionic homeostasis and reprogrammes gene expression networks, thus validating this transporter as a high-value target for therapeutic intervention.

Membrane Protein Targeting in Mycobacterial Drug Development publication trend

The graph below shows the total number of articles in membrane protein targeting in mycobacterial drug development across all publications each year (not limited to Nature Index journals).

Technical terms

Proton motive force: Electrochemical gradient of protons across the membrane that drives energy-dependent transport processes.

Allosteric coupling: Regulation of protein activity through conformational changes induced by ligand binding at a site distinct from the substrate-binding pocket.

MmpL proteins: Family of large inner-membrane transporters that export lipids crucial for mycobacterial cell-wall assembly and virulence.

Trehalose monomycolate (TMM): Glycolipid precursor of the outer-membrane component trehalose dimycolate, translocated by MmpL3.

Cryo-electron microscopy: Technique for determining high-resolution structures of macromolecules in near‐native states by imaging samples at cryogenic temperatures.

References

1. Structures of the mycobacterial MmpL4 and MmpL5 transporters provide insights into their role in siderophore export and iron acquisition. PLOS Biology (2024).
2. Inhibition Mechanism of Anti-TB Drug SQ109: Allosteric Inhibition of TMM Translocation of Mycobacterium Tuberculosis MmpL3 Transporter. Journal of Chemical Information and Modeling (2023).
3. Allosteric coupling of substrate binding and proton translocation in MmpL3 transporter from Mycobacterium tuberculosis. mBio (2024).
4. Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression. Scientific Reports (2017).